BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
VGLOCK|c^fyDLOCK|X#xvH$#

BioMérieux Earnings: Weak Respiratory Season Weighs on Sales; Shares Fairly Valued

BioMérieux reported 3.1% organic sales growth during the third quarter. Nonrespiratory molecular growth was partially offset by lower respiratory pathogen circulation and currency effects.

Sponsor Center